New preclinical data supports immuno-oncology approach
Filed with ASX · · 5 pages · English
Earlier from Noxopharm
- Quarterly Activities/Appendix 4C Cash Flow Report
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
Later from Noxopharm
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
- Trading Halt
- Voluntary Suspension
- Noxopharm Successfully Raises $1.5 Million via Placement
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm